Novo Nordisk is reportedly preparing to announce clinical trial results for a next-generation weight-loss drug. The company has not disclosed details about the drug or when it will announce the results.
The development marks a potential milestone in Novo Nordisk’s efforts to advance beyond its current blockbuster obesity treatments and maintain its position in the metabolic diseases market. The company is also expanding the reach of existing products such as Wegovy®.
Separately, Novo Holdings, Novo Nordisk’s controlling shareholder, co-led a $310 million financing round for UK-based biotech firm OMass Therapeutics on October 15, 2026.
Also on October 15, 2026, Novo Nordisk announced that Dr. Joanna Holbrook, a Therapy Area Head at the company, will leave to become Chief Scientific Officer at Evotec SE, effective November 1, 2026.